All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Androgen deprivation therapy (ADT) is still the main treatment option for locally advanced and metastatic prostate cancer (PCa); however, most patients receiving ADT develop resistance to treatment and relapse, with a more aggressive form of cancer, castration-resistant prostate cancer (CRPC).
HBM Alpha Therapeutics Inc. has completed seed financing to advance its lead programs, novel antibody therapies to treat congenital adrenal hyperplasia (CAH) and polycystic ovary syndrome (PCOS).
Centessa Pharmaceuticals plc has received clearance of its IND application from the FDA to initiate a first-in-human phase I/IIa trial of LB-101 for the treatment of solid tumors.
Astrazeneca AB and Mitsubishi Tanabe Pharma Corp. have divulged NLRP3 inflammasome inhibitors reported to be useful for the treatment of liver, autoimmune and inflammatory bowel disease, inflammation, respiratory, cardiovascular and renal disorders.
Janssen Pharmaceutica NV has identified 5-oxo-pyrido[2,3-d]pyridazin-6(5h)-yl acetamides acting as NLRP3 inflammasome inhibitors reported to be useful for the treatment of cancer, viral hepatitis, diabetes, immunological, inflammatory, neurological, cardiovascular and metabolic disorders.
Medshine Discovery Inc. has synthesized dimethyl-substituted thiazololactam compounds acting as mitogen-activated protein kinase 3 (MAPK3; ERK1) and/or (MAPK1; ERK2) inhibitors reported to be useful for the treatment of cancer.
Shanghai University of Traditional Chinese Medicine and Vestlandets Innovasjonsselskap AS (VIS) have disclosed bufalin derivatives acting as androgen receptor antagonists reported to be useful for the treatment of prostate cancer.
Genkore Inc. has entered into a strategic research collaboration with a U.S.-based biopharma company for the development of in vivo gene editing therapies.
RSS
